Moreover, nanoparticles designed to switch MDSCs into anti-tumor modes increase the production of anti-tumor cytokines, activate T cell activity, and extend mouse lifespan.875 Targeting MDSCs with HDL-like nanoparticles in a melanoma metastasis mouse model leads to increased CD8+ T cell numbers, reduced regulatory T cell numbers, slowed tumor growth, reduced tumor burden, and extended survival.876 Combination therapy delivering anti-cancer drugs via nanoparticles and modulating MDSCs shows promise in improving outcomes of cancer immunotherapy. Here, CD8A is linked to melanoma.